Your browser doesn't support javascript.
loading
Molecular Monitoring of Lymphomas.
Schroers-Martin, Joseph G; Alig, Stefan; Garofalo, Andrea; Tessoulin, Benoit; Sugio, Takeshi; Alizadeh, Ash A.
Affiliation
  • Schroers-Martin JG; Department of Medicine, Divisions of Hematology and Oncology, Stanford University Medical Center, Stanford, California, USA; email: arasha@stanford.edu.
  • Alig S; Department of Medicine, Divisions of Hematology and Oncology, Stanford University Medical Center, Stanford, California, USA; email: arasha@stanford.edu.
  • Garofalo A; Department of Medicine, Divisions of Hematology and Oncology, Stanford University Medical Center, Stanford, California, USA; email: arasha@stanford.edu.
  • Tessoulin B; Department of Medicine, Divisions of Hematology and Oncology, Stanford University Medical Center, Stanford, California, USA; email: arasha@stanford.edu.
  • Sugio T; Current affiliation: Clinical Hematology Department, Nantes University Hospital, Nantes, France.
  • Alizadeh AA; Department of Medicine, Divisions of Hematology and Oncology, Stanford University Medical Center, Stanford, California, USA; email: arasha@stanford.edu.
Annu Rev Pathol ; 18: 149-180, 2023 01 24.
Article in En | MEDLINE | ID: mdl-36130071
Molecular monitoring of tumor-derived alterations has an established role in the surveillance of leukemias, and emerging nucleic acid sequencing technologies are likely to similarly transform the clinical management of lymphomas. Lymphomas are well suited for molecular surveillance due to relatively high cell-free DNA and circulating tumor DNA concentrations, high somatic mutational burden, and the existence of stereotyped variants enabling focused interrogation of recurrently altered regions. Here, we review the clinical scenarios and key technologies applicable for the molecular monitoring of lymphomas, summarizing current evidence in the literature regarding molecular subtyping and classification, evaluation of treatment response, the surveillance of active cellular therapies, and emerging clinical trial strategies.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Circulating Tumor DNA / Lymphoma Limits: Humans Language: En Journal: Annu Rev Pathol Journal subject: PATOLOGIA Year: 2023 Document type: Article Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Circulating Tumor DNA / Lymphoma Limits: Humans Language: En Journal: Annu Rev Pathol Journal subject: PATOLOGIA Year: 2023 Document type: Article Country of publication: United States